Roche-Spark Deal's Mystery Delay Makes Investors Jittery

(Bloomberg) -- Delays from the Federal Trade Commission and concerns about the timing of Roche Holding AG’s planned $4.8 billion deal to buy small-cap drug developer Spark Therapeutics Inc. are sto...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.